July 23, 2024
View Full PaperTable 1 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Key Points
Key points are not available for this paper at this time.
Abstract
Baseline characteristics, SETD2 mutations, co-occurring mutations, sites of metastases, and prior therapies